{"id":"placebo-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Nocebo effects (adverse events attributed to placebo)"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo tablets","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:06:11.234681+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:06:16.836016+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo tablets","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:06:17.011453+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL942/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:06:17.710289+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo tablets contain no active pharmaceutical ingredients but can elicit measurable clinical improvements through patient expectation, conditioning, and activation of endogenous healing mechanisms. The placebo effect involves both psychological factors (belief and expectation) and neurobiological pathways (e.g., endogenous opioid release, dopamine signaling). This phenomenon is particularly effective for subjective symptoms such as pain, nausea, and fatigue.","oneSentence":"Placebo tablets produce therapeutic effects through the placebo effect, wherein the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:14.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:06:19.391269+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Research and clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31},{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT07485959","phase":"NA","title":"The Effect of NP-2006 on Sleep Quality and Health","status":"COMPLETED","sponsor":"Hanpoong Nature Pharm Co., Ltd.","startDate":"2023-05-12","conditions":"Sleep Disorder (Disorder)","enrollment":48},{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT07149649","phase":"PHASE2, PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT06344104","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-08","conditions":"Uncontrolled Hypertension, Resistant Hypertension","enrollment":326},{"nctId":"NCT06412666","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-05-29","conditions":"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","enrollment":55},{"nctId":"NCT07419828","phase":"PHASE3","title":"A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-13","conditions":"Chronic Kidney Disease","enrollment":1978},{"nctId":"NCT05327127","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kowa Research Institute, Inc.","startDate":"2022-11-14","conditions":"NASH","enrollment":228},{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT07497087","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-06-09","conditions":"Systemic Sclerosis","enrollment":448},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT05142735","phase":"NA","title":"Effects of NAC on Symptoms of CHR Patients","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-13","conditions":"Prodromal Schizophrenia","enrollment":90},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14},{"nctId":"NCT06993792","phase":"PHASE3","title":"A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-15","conditions":"Obesity, Overweight, Type 2 Diabetes","enrollment":1200},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06241313","phase":"PHASE3","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-03-25","conditions":"Migraine","enrollment":1300},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT06964776","phase":"PHASE1","title":"A Study of LY4268989 (MORF-057) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-01","conditions":"Healthy","enrollment":144},{"nctId":"NCT06280235","phase":"PHASE2","title":"A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-27","conditions":"Depressive Disorder, Major","enrollment":243},{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT05501678","phase":"PHASE2","title":"Trial of Diphenhydramine for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT07495995","phase":"PHASE2","title":"Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-04-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","enrollment":94},{"nctId":"NCT01113229","phase":"PHASE4","title":"Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-03","conditions":"Hemorrhage; Complicating Delivery","enrollment":1721},{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT07225504","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-11","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":1275},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT07497880","phase":"PHASE2","title":"Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-04-01","conditions":"Obesity, Overweight","enrollment":320},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT06972459","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-15","conditions":"Obesity, Overweight","enrollment":600},{"nctId":"NCT06679140","phase":"PHASE3","title":"A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-12-08","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":2330},{"nctId":"NCT07201129","phase":"PHASE3","title":"A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2026-02-09","conditions":"Nephritis, Lupus, Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT06082037","phase":"PHASE3","title":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-10-10","conditions":"Lung Transplant Rejection","enrollment":180},{"nctId":"NCT06752590","phase":"PHASE2","title":"A Clinical Study of ONO-1110 in Patients With Fibromyalgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-03-26","conditions":"Fibromyalgia","enrollment":160},{"nctId":"NCT06402123","phase":"PHASE2","title":"A Phase 2b Study of Zagociguat in Patients With MELAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tisento Therapeutics","startDate":"2024-09-10","conditions":"Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)","enrollment":43},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT07493265","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy","status":"NOT_YET_RECRUITING","sponsor":"Eisai Inc.","startDate":"2026-03-23","conditions":"Narcolepsy","enrollment":64},{"nctId":"NCT04394416","phase":"PHASE3","title":"Trial of Imatinib for Hospitalized Adults With COVID-19","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-02","conditions":"COVID-19","enrollment":21},{"nctId":"NCT04026997","phase":"PHASE2","title":"A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis","status":"TERMINATED","sponsor":"CinDome Pharma, Inc.","startDate":"2019-09-11","conditions":"Gastroparesis","enrollment":72},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT07230132","phase":"PHASE2","title":"Efficacy and Safety of ZT006 in Overweight and Obese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","startDate":"2025-12-12","conditions":"Overweight , Obesity","enrollment":184},{"nctId":"NCT07226661","phase":"PHASE2","title":"Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2026-01-19","conditions":"Major Depressive Disorder (MDD)","enrollment":230},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT05312879","phase":"PHASE2, PHASE3","title":"Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-03-30","conditions":"Proteinuric Kidney Disease","enrollment":466},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT06812078","phase":"PHASE2","title":"A Study of TAK-360 in Adults With Idiopathic Hypersomnia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-07","conditions":"Idiopathic Hypersomnia","enrollment":96},{"nctId":"NCT03941808","phase":"NA","title":"Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2019-06-17","conditions":"Vitiligo","enrollment":50},{"nctId":"NCT07144163","phase":"PHASE3","title":"A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-12-11","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT07489612","phase":"PHASE2","title":"QLS1410 in Participants With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hypertension (HTN)","enrollment":260},{"nctId":"NCT07388667","phase":"PHASE1","title":"A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT06217302","phase":"PHASE3","title":"Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Alessandro Doria","startDate":"2024-10-31","conditions":"Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1","enrollment":150},{"nctId":"NCT04774159","phase":"PHASE3","title":"Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-05-06","conditions":"Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation","enrollment":6150},{"nctId":"NCT03036995","phase":"PHASE2","title":"Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-03-20","conditions":"Vitiligo","enrollment":80},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT07489495","phase":"PHASE3","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-17","conditions":"Carcinoma, Renal Cell","enrollment":758},{"nctId":"NCT06319118","phase":"PHASE4","title":"A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-10-01","conditions":"Salivation in Parkinson's Disease","enrollment":120},{"nctId":"NCT05430230","phase":"PHASE4","title":"Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-24","conditions":"Osteoarthritis, Knee","enrollment":20},{"nctId":"NCT06006247","phase":"PHASE2","title":"Early Parkinson's Disease Monotherapy With CVN424","status":"COMPLETED","sponsor":"Cerevance Beta, Inc.","startDate":"2023-09-11","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT06655883","phase":"PHASE3","title":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-09","conditions":"Insomnia","enrollment":300},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT07487831","phase":"PHASE4","title":"The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-16","conditions":"Atopic Dermatitis (Eczema), Psoriasis","enrollment":50},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT05399368","phase":"PHASE2","title":"An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2022-06-07","conditions":"Atopic Dermatitis","enrollment":229},{"nctId":"NCT06637631","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Crohn's Disease","enrollment":260},{"nctId":"NCT06113445","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-29","conditions":"NonSegmental Vitiligo","enrollment":467},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT05452564","phase":"PHASE2","title":"Baricitinib for Reduction of HIV - CNS","status":"RECRUITING","sponsor":"William Tyor","startDate":"2023-05-18","conditions":"Human Immunodeficiency Virus","enrollment":95},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT06113471","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-27","conditions":"NonSegmental Vitiligo","enrollment":450},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT07485595","phase":"PHASE2, PHASE3","title":"A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2026-04-30","conditions":"Depression","enrollment":180},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT02425774","phase":"PHASE4","title":"Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2014-07","conditions":"Postoperative Ileus","enrollment":31},{"nctId":"NCT06547489","phase":"PHASE2","title":"Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2025-02-03","conditions":"Major Depressive Disorder","enrollment":164},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT04781543","phase":"PHASE2","title":"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-11-05","conditions":"Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic","enrollment":301},{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT05431088","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study in Adult and Adolescent Participants With SCD","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-09-22","conditions":"Sickle Cell Disease","enrollment":389},{"nctId":"NCT06667700","phase":"PHASE3","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-02","conditions":"Coronavirus Disease (COVID-19)","enrollment":3082},{"nctId":"NCT05217498","phase":"PHASE1, PHASE2","title":"Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Randy Trumbower, PT, PhD","startDate":"2027-09-01","conditions":"Spinal Cord Injuries, Myelopathy","enrollment":40},{"nctId":"NCT07202884","phase":"PHASE3","title":"A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-09-30","conditions":"Urinary Incontinence,Stress","enrollment":1000},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CARDIOVASCULAR DISORDER"},{"count":1,"reaction":"CATHETER SITE HAEMATOMA"},{"count":1,"reaction":"CATHETER SITE HAEMORRHAGE"},{"count":1,"reaction":"CLOSTRIDIUM COLITIS"},{"count":1,"reaction":"CYTOMEGALOVIRUS INFECTION"},{"count":1,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"DRUG HYPERSENSITIVITY"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"EPSTEIN-BARR VIRUS INFECTION"}],"crossReferences":{"chemblId":"CHEMBL942"},"_approvalHistory":[],"publicationCount":1230,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["2g of intravenous ceftriaxone or one β-lactam/β-lactamase combination(dose adjusted according to renal clearance) or 400mg of intravenous moxifloxacin","Placebo Placebo","Placebo","Suger pills","Juyuansuanjia Huanshi Pian"],"phase":"marketed","status":"active","brandName":"placebo tablets","genericName":"placebo tablets","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo tablets produce therapeutic effects through the placebo effect, wherein the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients. Used for Research and clinical trial control comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:06:19.391269+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}